Soleno Therapeutics plunges after short report from Scorpion Capital on price, drug safety

Soleno Therapeutics Inc. 

SLNO-7.48%

+ Free Alerts

 shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for children with Prader-Willi syndrome (PWS).

Vykat XR, a modified tablet version of a 50-year-old generic suspension, carries an annual cost of $500,000, the report claims.

https://www.benzinga.com/news/health-care/25/08/47163394/short-seller-alleges-soleno-only-commercial-drug-overpriced-and-unsafe